eli lilly retatrutide clinical trials Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In New Weight Loss Drug Retatrutide:

To view or add a comment, sign in The food and beverage landscape is evolving rapidly - and were only beginning to see the full impact of GLP-1 medications on consumer behaviour and category trends

Additional in vitro work by some of these groups might explain how GLP-1RAs modulate skin inflammation in PsO patients

This raises questions about dosage adjustments over time that the standard escalation charts do not address

The strongest preliminary evidence exists for alcohol use disorder, where both retrospective analyses and small prospective studies have shown promising signals

is on the speakers bureaus of and has served as a consultant for, received honoraria as a promotional speaker from, or participated in advisory boards for Abbott Laboratories, AstraZeneca, Bayer Laboratories, Boehringer Ingelheim, Lilly, Janssen Pharmaceuticals, Mylan Pharmaceuticals, and Novo Nordisk

Adding 2mL gives 5mg/mL (20 units = 1mg)